Literature DB >> 32641306

Omeprazole-induced hypomagnesaemia, causing renal tubular acidosis with hypokalaemia, hypocalcaemia, hyperlactacidaemia and hyperammonaemia.

Naohi Isse1, Masashi Hashimoto2.   

Abstract

A 72-year-old Japanese man treated with omeprazole for 11 years was admitted due to loss of consciousness and muscle weakness. Wolff-Parkinson-White syndrome-induced tachycardia was considered as the cause of syncope. His blood examination revealed rhabdomyolysis, hypokalaemia, hypomagnesaemia, hypocalcaemia, hyperlactacidaemia, hyperammonaemia and high-anion-gap metabolic acidosis. Hypomagnesaemia could be caused by magnesium malabsorption due to omeprazole use. Hypocalcaemia might be caused by the inhibitory effect of hypomagnesemia on the parathyroid gland hormone secretion. Hyperammonaemia might be caused by two reasons: (1) renal ammonium production induced by hypokalaemia; (2) inhibition of ammonium secretion by omeprazole. Both hypocalcaemia and hypokalaemia might cause chronic elevation of serum creatinine phosphokinase which ended up with rhabdomyolysis. Correction of serum electrolytes rapidly improved his muscle weakness. Discontinuation of omeprazole no longer caused these abnormalities. A physician should be aware of unexplained signs and symptoms of patients using proton-pump inhibitors to avoid life-threatening electrolyte and physiologic disturbances. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  fluid electrolyte and acid-base disturbances; metabolic disorders; renal system; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2020        PMID: 32641306      PMCID: PMC7348324          DOI: 10.1136/bcr-2020-235385

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Rhabdomyolysis.

Authors:  Russell Lane; Malcolm Phillips
Journal:  BMJ       Date:  2003-07-19

Review 2.  Renal Tubular Acidosis: H+/Base and Ammonia Transport Abnormalities and Clinical Syndromes.

Authors:  Ira Kurtz
Journal:  Adv Chronic Kidney Dis       Date:  2018-07       Impact factor: 3.620

Review 3.  Proton-pump inhibitor-induced hypomagnesemia: Current research and proposed mechanisms.

Authors:  Jeffrey H William; John Danziger
Journal:  World J Nephrol       Date:  2016-03-06

4.  A case series of proton pump inhibitor-induced hypomagnesemia.

Authors:  Ewout J Hoorn; Joost van der Hoek; Rob A de Man; Ernst J Kuipers; Clemens Bolwerk; Robert Zietse
Journal:  Am J Kidney Dis       Date:  2010-02-26       Impact factor: 8.860

Review 5.  Review of the Diagnostic Evaluation of Renal Tubular Acidosis.

Authors:  Julian Yaxley; Christine Pirrone
Journal:  Ochsner J       Date:  2016

Review 6.  Systematic review: hypomagnesaemia induced by proton pump inhibition.

Authors:  M W Hess; J G J Hoenderop; R J M Bindels; J P H Drenth
Journal:  Aliment Pharmacol Ther       Date:  2012-07-04       Impact factor: 8.171

Review 7.  Mechanism of hypokalemia in magnesium deficiency.

Authors:  Chou-Long Huang; Elizabeth Kuo
Journal:  J Am Soc Nephrol       Date:  2007-09-05       Impact factor: 10.121

8.  Low serum concentrations of 1,25-dihydroxyvitamin D in human magnesium deficiency.

Authors:  R K Rude; J S Adams; E Ryzen; D B Endres; H Niimi; R L Horst; J G Haddad; F R Singer
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

Review 9.  Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use.

Authors:  Yoshikazu Kinoshita; Norihisa Ishimura; Shunji Ishihara
Journal:  J Neurogastroenterol Motil       Date:  2018-04-30       Impact factor: 4.924

  9 in total
  1 in total

Review 1.  Common Pitfalls in the Management of Patients with Micronutrient Deficiency: Keep in Mind the Stomach.

Authors:  Marilia Carabotti; Bruno Annibale; Edith Lahner
Journal:  Nutrients       Date:  2021-01-13       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.